Caveolin-1-ACE2 axis modulates xenobiotic metabolism-linked chemoresistance in ovarian clear cell carcinoma
Tóm tắt
Among epithelial ovarian cancers, ovarian clear cell carcinoma (OCCC) remains markedly resistant to platinum-based chemotherapy, leading to poor clinical outcomes. In response to xenobiotic insults, caveolar platforms play crucial roles in modulating stress signaling responses in cancer cells. It has been hypothesized that caveolin-1 (Cav-1), a main component of the lipid raft, may regulate the response to platinum-based treatment in OCCC. The clinical transcriptomic evaluation demonstrated that high Cav-1 expression was positively associated with a favorable prognosis in patients with ovarian cancer. Cav-1 overexpression enhanced sensitivity to cisplatin (CDDP) treatment, whereas Cav-1 deficiency promoted chemoresistance in OCCC cells. Mechanistically, although Cav-1 counteracted angiotensin-converting enzyme 2 (ACE2) expression, ACE2 positively facilitated resistance to CDDP in OCCC cells. Furthermore, ACE2 restricted aryl hydrocarbon receptor expression and subsequent transcription of drug-metabolizing enzymes. Of note, ACE2 positively regulated the expression of the platinum-clearing enzyme CYP3A4. These findings suggest that the Cav-1-ACE2 axis modulates xenobiotic metabolism-linked chemoresistance in OCCC, predicting potential roles for the stress sentinel networks in oncogenic processes.
Tài liệu tham khảo
Belanger MM, Roussel E, Couet J. Caveolin-1 is down-regulated in human lung carcinoma and acts as a candidate tumor suppressor gene. Chest. 2004;125(5):106s-s. https://doi.org/10.1378/chest.125.5_suppl.106S.
Cai C, Chen J. Overexpression of caveolin-1 induces alteration of multidrug resistance in Hs578T breast adenocarcinoma cells. Int J Cancer. 2004;111(4):522–9. https://doi.org/10.1002/ijc.20300.
Chan KK, Dorosky D, Sharma P, Abbasi SA, Dye JM, Kranz DM, et al. Engineering human ACE2 to optimize binding to the spike protein of SARS coronavirus 2. Science. 2020;369(6508):1261–5. https://doi.org/10.1126/science.abc0870.
Chen HL, Fan LF, Gao J, Ouyang JP, Zhang YX. Differential expression and function of the caveolin-1 gene in non-small cell lung carcinoma. Oncol Rep. 2011;25(2):359–66. https://doi.org/10.3892/or.2010.1095.
Cheng Q, Zhou L, Zhou J, Wan H, Li Q, Feng Y. ACE2 overexpression inhibits acquired platinum resistance-induced tumor angiogenesis in NSCLC. Oncol Rep. 2016;36(3):1403–10. https://doi.org/10.3892/or.2016.4967.
Chung YC, Kuo JF, Wei WC, Chang KJ, Chao WT. Caveolin-1 dependent endocytosis enhances the chemosensitivity of HER-2 positive breast cancer cells to trastuzumab emtansine (T-DM1). Plos One. 2015;10(7):e0133072. https://doi.org/10.1371/journal.pone.0133072.
Ciardiello F, Caputo R, Bianco R, Damiano V, Fontanini G, Cuccato S, et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001;7(5):1459–65.
Couet J, Sargiacomo M, Lisanti MP. Interaction of a receptor tyrosine kinase, EGF-R, with caveolions. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem. 1997;272(48):30429–38. https://doi.org/10.1074/jbc.272.48.30429.
Deuster E, Mayr D, Hester A, Kolben T, Zeder-Goss C, Burges A, et al. 2019 Correlation of the aryl hydrocarbon receptor with FSHR in ovarian cancer patients. Int J Mol Sci. 20(12). doi: https://doi.org/10.3390/ijms20122862.
Dittmann K, Mayer C, Kehlbach R, Rodemann HP. Radiation-induced caveolin-1 associated EGFR internalization is linked with nuclear EGFR transport and activation of DNA-PK. Mol Cancer. 2008;7:69. https://doi.org/10.1186/1476-4598-7-69.
Feng S, Cao Z, Wang X. Role of aryl hydrocarbon receptor in cancer. Biochim Biophys Acta. 2013;1836(2):197–210. https://doi.org/10.1016/j.bbcan.2013.05.001.
Fujimoto T, Kogo H, Nomura R, Une T. Isoforms of caveolin-1 and caveolar structure. J Cell Sci. 2000;113(Pt 19):3509–17.
Goldstein I, Rivlin N, Shoshana OY, Ezra O, Madar S, Goldfinger N, et al. Chemotherapeutic agents induce the expression and activity of their clearing enzyme CYP3A4 by activating p53. Carcinogenesis. 2013;34(1):190–8. https://doi.org/10.1093/carcin/bgs318.
Gui T, Shen K. The epidermal growth factor receptor as a therapeutic target in epithelial ovarian cancer. Cancer Epidemiol. 2012;36(5):490–6. https://doi.org/10.1016/j.canep.2012.06.005.
Gupta R, Toufaily C, Annabi B. Caveolin and cavin family members: dual roles in cancer. Biochimie. 107 Pt B:188–202. doi: https://doi.org/10.1016/j.biochi.2014.09.010.
Hennighausen L, Lee HK. Activation of the SARS-CoV-2 Receptor Ace2 by cytokines through pan JAK-STAT enhancers. SSRN. 2020:3601827. doi: https://doi.org/10.2139/ssrn.3601827.
Ho CC, Kuo SH, Huang PH, Huang HY, Yang CH, Yang PC. Caveolin-1 expression is significantly associated with drug resistance and poor prognosis in advanced non-small cell lung cancer patients treated with gemcitabine-based chemotherapy. Lung Cancer. 2008;59(1):105–10. https://doi.org/10.1016/j.lungcan.2007.07.024.
Ho CM, Huang YJ, Chen TC, Huang SH, Liu FS, Chang Chien CC, et al. Pure-type clear cell carcinoma of the ovary as a distinct histological type and improved survival in patients treated with paclitaxel-platinum-based chemotherapy in pure-type advanced disease. Gynecol Oncol. 2004;94(1):197–203. https://doi.org/10.1016/j.ygyno.2004.04.004.
Hose CD, Hollingshead M, Sausville EA, Monks A. Induction of CYP1A1 in tumor cells by the antitumor agent 2-[4-amino-3-methylphenyl]-5-fluoro-benzothiazole: a potential surrogate marker for patient sensitivity. Mol Cancer Ther. 2003;2(12):1265–72.
Kai WC, Diatchenko L, Agoulnik A, Scharff KM, Schober H, Arlt K, et al. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am J Pathol. 2001;159(5):1635–43. https://doi.org/10.1016/S0002-9440(10)63010-6.
Khanna P, Soh HJ, Chen CH, Saxena R, Amin S, Naughton M, et al. ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1–7) as a therapy for clear cell renal cell carcinoma. Sci Transl Med. 13(577). doi: https://doi.org/10.1126/scitranslmed.abc0170.
Kim HJ, Yoon A, Ryu JY, Cho YJ, Choi JJ, Song SY, et al. c-MET as a potential therapeutic target in ovarian clear cell carcinoma. Sci Rep. 2016;6:38502. https://doi.org/10.1038/srep38502.
Krishnan B, Torti FM, Gallagher PE, Tallant EA. Angiotensin-(1–7) reduces proliferation and angiogenesis of human prostate cancer xenografts with a decrease in angiogenic factors and an increase in sFlt-1. Prostate. 2013;73(1):60–70. https://doi.org/10.1002/pros.22540.
Kwok ALM, Wong OGW, Wong ESY, Tsun OKL, Chan KK, Cheung ANY. Caution over use of ES2 as a model of ovarian clear cell carcinoma. J Clin Pathol. 2014;67(10):921–2. https://doi.org/10.1136/jclinpath-2014-202430.
Lee SW, Reimer CL, Oh P, Campbell DB, Schnitzer JE. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene. 1998;16(11):1391–7. https://doi.org/10.1038/sj.onc.1201661.
Liu SL, Premont RT, Singh S, Rockey DC. Caveolin 1 and G-protein-coupled receptor kinase-2 coregulate endothelial nitric oxide synthase activity in sinusoidal endothelial cells. Am J Pathol. 2017;187(4):896–907. https://doi.org/10.1016/j.ajpath.2016.11.017.
Lv JD, Yu P, Wang ZF, Deng W, Bao LL, Liu JN, et al. ACE2 expression is regulated by AhR in SARS-CoV-2-infected macaques. Cell Mol Immunol. 2021;18(5):1308–10. https://doi.org/10.1038/s41423-021-00672-1.
Masek V, Anzenbacherova E, Machova M, Brabec V, Anzenbacher P. Interaction of antitumor platinum complexes with human liver microsomal cytochromes P450. Anticancer Drugs. 2009;20(5):305–11. https://doi.org/10.1097/cad.0b013e328323a7a8.
Niikura H, Sasano H, Sato S, Yajima A. Expression of epidermal growth factor-related proteins and epidermal growth factor receptor in common epithelial ovarian tumors. Int J Gynecol Pathol. 1997;16(1):60–8. https://doi.org/10.1097/00004347-199701000-00010.
Ohe T, Hirobe M, Mashino T. Novel metabolic pathway of estrone and 17 beta-estradiol catalyzed by cytochrome P-450. Drug Metab Dispos. 2000;28(2):110–2.
Orezzoli JP, Russell AH, Oliva E, Del Carmen MG, Eichhorn J, Fuller AF. Prognostic implication of endometriosis in clear cell carcinoma of the ovary. Gynecol Oncol. 2008;110(3):336–44. https://doi.org/10.1016/j.ygyno.2008.05.025.
Park SH, Kim J, Moon Y. Caveolar communication with xenobiotic-stalled ribosomes compromises gut barrier integrity. Commun Biol. 2020;3(1):270. https://doi.org/10.1038/s42003-020-0994-1.
Pelkmans L, Helenius A. Insider information: what viruses tell us about endocytosis. Curr Opin Cell Biol. 2003;15(4):414–22. https://doi.org/10.1016/s0955-0674(03)00081-4.
Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell. 1992;68(4):673–82. https://doi.org/10.1016/0092-8674(92)90143-z.
Safe S, Lee SO, Jin UH. Role of the aryl hydrocarbon receptor in carcinogenesis and potential as a drug target. Toxicol Sci. 2013;135(1):1–16. https://doi.org/10.1093/toxsci/kft128.
Scripture CD, Sparreboom A, Figg WD. Modulation of cytochrome P450 activity: implications for cancer therapy. Lancet Oncol. 2005;6(10):780–9. https://doi.org/10.1016/S1470-2045(05)70388-0.
Shajahan AN, Wang AF, Decker M, Minshall RD, Liu MC, Clarke R. Caveolin-1 tyrosine phosphorylation enhances paclitaxel-mediated cytotoxicity. J Biol Chem. 2007;282(8):5934–43. https://doi.org/10.1074/jbc.M608857200.
Sieczkarski SB, Whittaker GR. Dissecting virus entry via endocytosis. J Gen Virol. 2002;83(Pt 7):1535–45. https://doi.org/10.1099/0022-1317-83-7-1535.
Stejskalova L, Dvorak Z, Pavek P. Endogenous and exogenous ligands of aryl hydrocarbon receptor: current state of art. Curr Drug Metab. 2011;12(2):198–212. https://doi.org/10.2174/138920011795016818.
Sugiyama T, Kamura T, Kigawa J, Terakawa N, Kikuchi Y, Kita T, et al. Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000;88(11):2584–9.
Tirado OM, MacCarthy CM, Fatima N, Villar J, Mateo-Lozano S, Notario V. Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing’s sarcoma cells by modulating PKCalpha phosphorylation. Int J Cancer. 2010a;126(2):426–36. https://doi.org/10.1002/ijc.24754.
Tirado OM, MacCarthy CM, Fatima N, Villar J, Mateo-Lozano S, Notario V. Caveolin-1 promotes resistance to chemotherapy-induced apoptosis in Ewing’s sarcoma cells by modulating PKC alpha phosphorylation. Int J Cancer. 2010b;126(2):426–36. https://doi.org/10.1002/ijc.24754.
Vihanto MM, Vindis C, Djonov V, Cerretti DP, Huynh-Do U. Caveolin-1 is required for signaling and membrane targeting of EphB1 receptor tyrosine kinase. J Cell Sci. 2006;119(11):2299–309. https://doi.org/10.1242/jcs.02946.
Wang Z, Wang N, Li W, Liu P, Chen Q, Situ H, et al. Caveolin-1 mediates chemoresistance in breast cancer stem cells via beta-catenin/ABCG2 signaling pathway. Carcinogenesis. 2014;35(10):2346–56. https://doi.org/10.1093/carcin/bgu155.
Williams TM, Medina F, Badano I, Hazan RB, Hutchinson J, Muller WJ, et al. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo. Role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J Biol Chem. 2004;279(49):51630–46. https://doi.org/10.1074/jbc.M409214200.
Xu J, Agyemang S, Qin Y, Aysola K, Giles M, Oprea G, et al. 2014 A novel pathway that links caveolin-1 down-regulation to BRCA1 dysfunction in serous epithelial ovarian cancer cells. Enliven Chall Cancer Detect Ther. 1(1). doi: https://doi.org/10.18650/2376-046x.11004.
Yamazaki H, Shaw PM, Guengerich FP, Shimada T. Roles of cytochromes P450 1A2 and 3A4 in the oxidation of estradiol and estrone in human liver microsomes. Chem Res Toxicol. 1998;11(6):659–65. https://doi.org/10.1021/tx970217f.
Yan B, Liu S, Shi Y, Liu N, Chen L, Wang X, et al. Activation of AhR with nuclear IKKalpha regulates cancer stem-like properties in the occurrence of radioresistance. Cell Death Dis. 2018;9(5):490. https://doi.org/10.1038/s41419-018-0542-9.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138(1):103–41. https://doi.org/10.1016/j.pharmthera.2012.12.007.
Zhang Q, Lu S, Li T, Yu L, Zhang Y, Zeng H, et al. ACE2 inhibits breast cancer angiogenesis via suppressing the VEGFa/VEGFR2/ERK pathway. J Exp Clin Cancer Res. 2019;38(1):173. https://doi.org/10.1186/s13046-019-1156-5.
Zou W, Ma XD, Hua W, Chen BL, Cai GQ. Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian cancer cells by targeting apoptosis through the Notch-1/Akt/NF-kappa B pathway. Oncol Rep. 2015;34(6):3256–63. https://doi.org/10.3892/or.2015.4320.